Chester County News and Community Website
Trevena, Inc. (Nasdaq: TRVN), headquartered in Chesterbrook, PA, is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) has announced a reverse stock split of its common stock at a ratio of 1-for-25. The split will take effect at 12:01 a.m. …
Trevena Announces Reverse Stock Split to Regain Nasdaq Compliance Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) has announced its financial results for the second quarter ended June 30, 2024, along with key operational updates.
Navigating Trevena’s Potential: Buy, Sell, or Hold? Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) has announced a significant amendment to its existing royalty-based financing agreement with R-Bridge Healthcare Fund, L.P. This amendment brings both immediate and potential …
Trevena Secures New Financing Amendment with R-Bridge Healthcare Fund Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), announced key data today from two separate preclinical studies. The data provides fascinating insights into the potential effects of TRV045, a novel S1P1 …
Revolutionary Preclinical Data Unveiled by Trevena: Potential New Direction in Neuropathic Pain and Acute Seizure Management Read More CHESTERBROOK, PA — Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company, spotlighted its first-quarter achievements and financial standing, underscoring advancements in its novel treatment for chronic pain and epilepsy and strategic …
Trevena Reports Progress in Pain and Epilepsy Treatment Development, Amid Financial Adjustments Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a leading pharmaceutical company, has recently unveiled its financial outcomes for the closing quarter of 2023, amidst a pivotal shift in their corporate …
Trevena Ramps Up Efforts on TRV045, Turns Attention Away from OLINVYK Amid Challenging Hospital Environment Read More CHESTERBROOK, PA — Pharmaceutical firm Trevena, Inc. (Nasdaq: TRVN) has recently completed two significant financial transactions, raising approximately $4 million in gross proceeds. The Chesterbrook, Pennsylvania-based company announced its successful …
Trevena Inc. Raises $4 Million in Private Stock and Warrant Offerings Read More CHESTERBROOK, PA — Trevena Inc. (NASDAQ: TRVN) has announced that it has secured a national group purchasing agreement with Premier Inc. for its product, OLINVYK. The agreement came into effect …
Trevena Inc. Secures National Group Purchasing Agreement for OLINVYK with Premier Inc. Read More CHESTERBROOK, PA — Biopharmaceutical company Trevena, Inc. (Nasdaq: TRVN), known for its innovative work in developing and commercializing novel medicines for central nervous system disorders, recently announced the acceptance of …
Trevena’s Investigator-Led RELIEVE Study Accepted for Presentation at 2024 American Burn Association Meeting Read More CHESTERBROOK, PA — Biopharmaceutical company Trevena, Inc. (NASDAQ: TRVN) has reported its Q3 2023 financial results, shedding light on a net loss attributable to common stockholders of $7.9 million, or …
Trevena Reports Promising Q3 2023 Results, Reveals Progress in TRV045 Studies and OLINVYK Sales Read More